⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HCM News
HUTCHMED (China) Limited American Depositary Shares
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
globenewswire.com
HCM
AZN
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
globenewswire.com
HCM
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
globenewswire.com
HCM
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
globenewswire.com
HCM
AZN
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
globenewswire.com
HCM
LLY
AZN
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
prnewswire.com
ONCY
HCM
CGON
CCCC
IDYA
ONCY
HCM
CGON
CCCC
IDYA